These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24819453)

  • 1. Comment on Lee et al.: incidence of second hip fracture and compliant use of bisphosphonate.
    Zhu Y; Chen W; Zhang Y
    Osteoporos Int; 2014 Sep; 25(9):2325. PubMed ID: 24819453
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of second hip fracture and compliant use of bisphosphonate.
    Lee YK; Ha YC; Yoon BH; Koo KH
    Osteoporos Int; 2013 Jul; 24(7):2099-104. PubMed ID: 23247329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis.
    Jansen JP; Bergman GJ; Huels J; Olson M
    Semin Arthritis Rheum; 2011 Feb; 40(4):275-84.e1-2. PubMed ID: 20828791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
    Wang Z; Ward MM; Chan L; Bhattacharyya T
    Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary fracture prevention after femur fractures in the Gran Canaria North Health Area: A 2004-2014 comparison.
    Naranjo A; Ojeda-Bruno S; Bilbao Cantarero A; Rodríguez-Moreno S
    Reumatol Clin; 2016; 12(1):58. PubMed ID: 26024587
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures .
    Meijer WM; Penning-van Beest FJ; Olson M; Herings RM
    Curr Med Res Opin; 2008 Nov; 24(11):3217-22. PubMed ID: 18922215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
    Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
    JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials.
    Wilkes MM; Navickis RJ; Chan WW; Lewiecki EM
    Osteoporos Int; 2010 Apr; 21(4):679-88. PubMed ID: 19572092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate use after clinical fracture and risk of new fracture.
    Bergman J; Nordström A; Nordström P
    Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
    Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
    Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
    Bondo L; Eiken P; Abrahamsen B
    Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
    Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
    Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Innovation of bisphosphonates for improvement of adherence.].
    Takeuchi Y
    Clin Calcium; 2017; 27(2):197-202. PubMed ID: 28123121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study.
    Kim SC; Kim MS; Sanfélix-Gimeno G; Song HJ; Liu J; Hurtado I; Peiró S; Lee J; Choi NK; Park BJ; Avorn J
    Am J Med; 2015 May; 128(5):519-26.e1. PubMed ID: 25660252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fracture Risk During and After Bisphosphonate Drug Holidays: A Matter of Methods?
    Adams AL
    Med Care; 2020 May; 58(5):417-418. PubMed ID: 32149922
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.